Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alflutinib vs Gefitinib in EGFR-Mutated NSCLC (FlAG)
NCT03787992Phase 3Active, not recruiting
- Sponsor
- Allist Pharmaceuticals
- Start
- May 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started May 2019; status: active, not recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03787992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787992.